Cure My Disease

Don't miss your cure!

 Log in / Sign up

Drug trial aims to shield kidneys during risky heart operations

NCT ID NCT05524051

Terminated Prevention Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study tested whether an experimental drug called TIN816 could prevent acute kidney injury in adults undergoing major heart surgery. About 98 patients at risk for kidney problems were randomly assigned to receive either TIN816 or a placebo. The trial was terminated early and aimed to see if the drug could protect kidney function in the days and months following surgery.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY FOLLOWING CARDIAC SURGERY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Duke Univ Medical Center

    Durham, North Carolina, 27710, United States

  • Mayo Clinic Phoenix

    Phoenix, Arizona, 85054, United States

  • Novartis Investigative Site

    CABA, Buenos Aires, C1118AAT, Argentina

  • Novartis Investigative Site

    Buenos Aires, C1428DCO, Argentina

  • Novartis Investigative Site

    CABA, C1181ACH, Argentina

  • Novartis Investigative Site

    Genk, Limburg, 3600, Belgium

  • Novartis Investigative Site

    Leuven, 3000, Belgium

  • Novartis Investigative Site

    São Paulo, São Paulo, 05403 000, Brazil

  • Novartis Investigative Site

    Salvador, 40323-010, Brazil

  • Novartis Investigative Site

    Montreal, Quebec, H1T 1C8, Canada

  • Novartis Investigative Site

    Montreal, Quebec, H2X 0A9, Canada

  • Novartis Investigative Site

    Montreal, Quebec, H4J 1C5, Canada

  • Novartis Investigative Site

    Québec, Quebec, GIV 4G5, Canada

  • Novartis Investigative Site

    Ostrava, Poruba, 708 52, Czechia

  • Novartis Investigative Site

    Tartu, 50406, Estonia

  • Novartis Investigative Site

    Nantes, 44093, France

  • Novartis Investigative Site

    Neuilly-sur-Seine, 92200, France

  • Novartis Investigative Site

    Paris, 75013, France

  • Novartis Investigative Site

    Poitiers, 86021, France

  • Novartis Investigative Site

    Rennes, 35033, France

  • Novartis Investigative Site

    Regensburg, Bavaria, 93053, Germany

  • Novartis Investigative Site

    Dresden, Saxony, 01307, Germany

  • Novartis Investigative Site

    Leipzig, Saxony, 04289, Germany

  • Novartis Investigative Site

    Essen, 45147, Germany

  • Novartis Investigative Site

    Pécs, Baranya, 7623, Hungary

  • Novartis Investigative Site

    Debrecen, Hajdu Bihar Megye, 4032, Hungary

  • Novartis Investigative Site

    Budapest, H 1096, Hungary

  • Novartis Investigative Site

    Budapest, H-1083, Hungary

  • Novartis Investigative Site

    Ahmedabad, Gujarat, 380054, India

  • Novartis Investigative Site

    Lucknow, Uttar Pradesh, 226003, India

  • Novartis Investigative Site

    Vilnius, LT-08406, Lithuania

  • Novartis Investigative Site

    Singapore, 119074, Singapore

  • Novartis Investigative Site

    Santiago Compostela, A Coruna, 15706, Spain

  • Novartis Investigative Site

    Badalona, Barcelona, 08916, Spain

  • Novartis Investigative Site

    L'Hospitalet de Llobregat, Barcelona, 08907, Spain

  • Novartis Investigative Site

    Madrid, 28006, Spain

  • Novartis Investigative Site

    Taipei, 10002, Taiwan

Conditions

Explore the condition pages connected to this study.

ACUTE KIDNEY INJURY FOLLOWING CARDIAC SURGERY